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Juvenile xanthogranuloma (JXG) is a histiocytic disorder that is usually benign and limited to the skin. Usually it regresses sponta-
neously, more often without or with limited skin changes. The systemic form of JXG is rare and may be associated with severe morbidity
and mortality due to CNS involvement. Here, we describe a 15 year old boy with puzzling skin lesions evolving since last 6 months on the
neck. A skin biopsy and immunohistochemistry conﬁrmed the diagnosis of JXG.
 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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JXG is one of the non-Langerhans histiocytic prolifera-
tive disorders. Histiocytosis is an uncommon disorder of
proliferation of histiocytes with Langerhans cell histiocyto-
sis (LCH) representing one group of disorders and non-
Langerhans cell histiocytosis (non-LCH) representing
another. Of note, each group represents a spectrum of dis-
ease, with overlap between entities. JXG is the most com-
mon histiocytic disorder usually aﬀecting infants and
young children with the involvement of the head and neck
region and upper body (Caputo, 1998). However, it pre-
sents at birth in 20% of cases and up to 10% in adults.http://dx.doi.org/10.1016/j.jdds.2014.06.001
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Production and hosting by ElsevierGiant JXG was deﬁned as lesion more than 20 mm. Extra-
cutaneous lesions have been reported in many organs, the
eye being most commonly aﬀected followed by the lung,
also liver, spleen and central nervous system (CNS) can
be involved. Systemic JXG is rare with a benign clinical
course but it occasionally has a poor prognosis (Dehner,
2003). Cutaneous JXG is most often a self-limiting disease
that regresses spontaneously and lesions may resolve com-
pletely or may leave a residual atrophic or hyperpigmented
scar (Tatiana and Ronald, 2008).2. Case presentation
A 15 year old boy, was referred to the dermatology
clinic for evaluation of two asymptomatic atrophic skin
lesions on the neck (Fig. 1a). According to the patient,
the lesions had enlarged since it was ﬁrst noted 6 months
before the visit to the clinic as elevated reddish lesions
and then changed to more depressed areas soon before
presentation. He had no abnormality at birth or historySaud University.
commons.org/licenses/by-nc-nd/3.0/).
Figure 1. (a) Two circumscribed atrophic plaques on the neck. (b) There is some telangiectasia and yellowish hue in a higher magniﬁcation.
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looking child with stable vital signs and normal growth
parameters. No dysmorphic features were noted. The
lesions presented as two circumscribed atrophic plaques
located at the right side of the neck, the bigger one measur-
ing 3  2 cm in diameter (Fig. 1b). They were mildly shiny,
with some evidence of telangiectasia overlying yellowish
hue at some points. No other lesions were found elsewhere.
Examination of mucous membranes was normal.
The patient underwent a punch biopsy under local anes-
thesia, the biopsy was ﬁxed in formalin, embedded in par-
aﬃn and stained with hematoxylin & eosin. Histological
evaluation of the lesion revealed unremarkable epidermis
with dermal chronic inﬂammation composing of lympho-
histiocytes, few plasma cells and rare eosinophils in the
background of ﬁbrosis. Vacuolated cells, few foam cells
and rare foreign body giant cells were noted but no touton
giant cells. Ziehl–Neelsen stain and ﬁte stain were negative.
The immunohistochemistry analysis demonstrated that the
histiocytic cells were positive for CD68 (Fig. 2). In light of
the clinical and histological ﬁndings, a diagnosis of late
onset giant JXG was made. The punch biopsy site was epi-
thelialized uneventfully and resulted in a minimal scar. The
patient referred to ophthalmology examination was found
to be unremarkable. Basic laboratory work up including
CBC, renal and liver functions was within normal limits.
Looking at the benign course of the disease with ongo-
ing spontaneous regression and absence of any speciﬁc
therapy, patient was discharged with an advice for a regu-
lar yearly follow-up.3. Discussion
JXG is the most common non-Langerhans cell histiocy-
tosis (LCH) in children. Cutaneous presentation consists of
red, yellow or brown papular lesions, usually asymptom-
atic, primarily involving the head, neck, and trunk. There
is a male predominance in all types of clinical presentation,
but especially notable in the group presenting with multiple
lesions on the skin (Dehner, 2003). A solitary cutaneous
lesion accounts for 67% of cases, followed by a solitary
subcutaneous or deep soft tissue mass in 16%, multiple
cutaneous lesions in 7% and multiple cutaneous and vis-
ceral-systemic lesions represent 5% of cases (Dehner, 2003).
Cutaneous JXG lesions are believed to be benign and
the most signiﬁcant clinical feature is the spontaneous
involution without any trace, although a ﬂat, atrophic scar
or an area of altered pigmentation can result (Sannier et al.,
2003). Systemic JXG is rare and many organs can be
involved including: eyes, lung, liver, spleen and central ner-
vous system. Usually it has a benign course without caus-
ing damage to the organs involved, except CNS
involvement which can be associated with severe morbidity
and mortality.
Although eye is the most common of organs aﬀected,
routine screening for ocular involvement is not performed
because of its low incidence. The eye probably is aﬀected
in only about 0.5% of patients with cutaneous JXG
(Liang et al., 2009), although some early studies found an
incidence as high as 10% (Vendal et al., 2006; Karcioglu
and Mullaney, 1997). Those at the greatest risk for eye
Figure 2. (a) Sheet like nodular aggregates of histiocytes, lymphocytes, eosinophils and rare foreign body giant cells in the dermis. (b) Note the vacuolated
cells and no touton giant cells. (c) Positive CD68.
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ple skin lesions. The most common ocular presentation
involves the iris.
Histologically, JXG is the prototype of non-Langerhans
cell histiocytosis. Most examples of JXG are easy to recog-
nize even at low power with its striking touton giant cells
embedded in sheet like nodular aggregates of histiocytes,
lymphocytes, and eosinophils admixed with foam cells.
But some examples of JXG can be quite challenging espe-
cially very early or late lesions. Generally skin lesions have
lives just as human beings have lives and lesions can look
very diﬀerent at diﬀerent times in their lives just as human
beings do. Stages in the lives of lesions can be described
roughly as early, fully developed and late. Here, we will
walk you through the histopathological ﬁndings in diﬀerent
stages of JXG. In very early lesion we just see a diﬀuse pat-
tern of vacuolated histiocytic inﬁltrate without giant cells
in the background of inﬂammatory cells corresponding to
the early erythematous papules clinically. In fact there
are 5 cell types involved in non-Langerhans histiocytosis;
vacuolated, xanthomatized, spindle-shaped, scalloped and
oncocytic cells. It is very useful to be aware of these cell
types because certain cell types tend to dominate in some
examples of JXG (Zelger et al., 1996) like our case. Fullydeveloped lesion contains foam cells, touton giant cells
corresponding to the usual yellowish color of JXG clini-
cally. In late lesion, ﬁbrosis within the mixed cell inﬁltrate
of histiocytes, lymphocytes and eosinophils corresponds to
the red brown color of the lesion clinically.
In cases presenting with cutaneous involvement, the size
of the lesion most likely does not alter the clinical course or
result in extracutaneous involvement, which remains rare.
In our report, the patient presented with giant JXG but
his other clinical examinations and basic laboratory work
up were within normal which could indicate no further
involvements. In one report, a 9-month-old boy who had
an extensive atrophic lesion on the proximal thigh that fol-
lowed the course of the congenital giant form does not
have extracutaneous involvement (Imiela et al., 2004).
According to our patient his JXG ﬁrst started as elevated
lesions which enlarged initially and then changed to another
morphology before his late presentation to the clinic with
the picture of wide atrophic plaques. Usually the diagnosis
of JXG when present in the classical picture as solitary or
multiple yellowish papules or nodules is not diﬃcult, how-
ever, in our report there are factors that caused some delay
in the diagnosis including: the age of the patient, atypical
clinical presentation in addition to late consultation after
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problem of diﬀerential diagnosis and by the end biopsy
was required to conﬁrm our impression and eliminate other
conditions with a less favorable prognosis.
Various authors have reported many cases of late or
adult onset JXG, some even have multiple lesions, that is
why many dermatologists prefer to omit the term Juvenile
from such cases. In adult cases detailed laboratory investi-
gations for extracutaneous JXG are not indicated, unless
there are symptoms or ﬁndings necessitate that (Achar
et al., 2011; Punithwavathy et al., 1999; Nayak et al.,
2009). It is worth mentioning that giant JXG should be dif-
ferentiated from JXG en plaque which is a very rare variant
that has been reported, used to deﬁne the group of JXG
lesions with tendency to coalesce into a plague (Vanotti
et al., 2014).
In summary, we reported a case with late onset JXG
that regressed spontaneously and resulted in a wide
atrophic scar. Recognition of this unique and unusual pre-
sentation of JXG clinically and histopathologically is
important for the clinician and pathologist, alike.
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